Last updated on November 2019

A Phase 3 Study With P2B001 in Subjects With Early Parkinson's


Brief description of study

A Phase 3, Twelve-week, Multi-Center, Multinational, Randomized, Double-Blind, Double-Dummy, Parallel Group Study to Determine the Efficacy, Safety and Tolerability of P2B001 Once Daily Compared to its Individual Components in Subjects With Early Parkinson's Disease and to a Calibration Arm of Pramipexole ER.

Detailed Study Description

A total of 525 eligible subjects with early untreated Parkinson's disease (PD), will be randomized to 4 treatment groups. Each subject will participate in the study for approximately 18 weeks including a 30 day screening period, 12 week treatment period, and 2 weeks follow-up period.

Clinical Study Identifier: NCT03329508

Find a site near you

Start Over

P2B001/003 Site Sarasota

Sarasota, FL United States
3.62miles
  Connect »